Yousefipour Zivar, Newaz Mohammad
College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX, USA.
College of Pharmacy, Chicago State University, Chicago, IL USA.
Acta Pharmacol Sin. 2014 Apr;35(4):476-82. doi: 10.1038/aps.2013.193. Epub 2014 Feb 24.
Peroxisome proliferator activated receptors (PPARs) are nuclear transcription factors that regulate numerous genes influencing blood pressure. The aim of this study was to examine the effects of clofibrate, a PPARα ligand, on blood pressure in spontaneously hypertensive rats (SHR).
Wistar-Kyoto (WKY) and spontaneously hypertensive rats (SHR), 8-9 weeks old, were randomly allocated into groups treated with vehicle or clofibrate (250 mg·kg(-1)·d(-1), ip for 21 d). Systolic blood pressure (SBP) was measured before and after the study period using tail-cuff plethysmography. Rats were sacrificed under anesthesia and blood, urine and tissue samples were processed for subsequent analysis.
SHR rats showed significantly higher SBP compared with WKY rats (198±6 mmHg vs 93±7 mmHg), and a 3-fold increase in urinary protein excretion. Clofibrate treatment reduced SBP by 26%±2% and proteinuria by 43%±9% in SHR but not in WKY rats. The urinary nitrite/nitrate excretion in SHR rats was nearly 2-fold greater than that in WKY, and was further increased by 30%±4% and 48%±3%, respectively, following clofibrate treatment. In addition, PPARα protein expression and PPARα activity were significantly lower in SHR than that in WKY rats. Clofibrate treatment significantly increased PPARα protein expression and PPARα activity in SHR rats, but not in WKY rats. Moreover, the vasoconstrictor response of aortic ring was markedly increased in SHRs, which was blunted after clofibrate treatment.
PPARα contributes to regulation of blood pressure and vascular reactivity in SHR, and clofibrate-mediated reduction in blood pressure and proteinuria is probably through increased NO production.
过氧化物酶体增殖物激活受体(PPARs)是调节众多影响血压基因的核转录因子。本研究旨在探讨PPARα配体氯贝丁酯对自发性高血压大鼠(SHR)血压的影响。
将8 - 9周龄的Wistar - Kyoto(WKY)大鼠和自发性高血压大鼠(SHR)随机分为接受溶剂或氯贝丁酯(250 mg·kg⁻¹·d⁻¹,腹腔注射,共21天)治疗的组。在研究期前后使用尾套体积描记法测量收缩压(SBP)。大鼠在麻醉下处死,采集血液、尿液和组织样本用于后续分析。
与WKY大鼠相比,SHR大鼠的SBP显著更高(198±6 mmHg对93±7 mmHg),尿蛋白排泄增加了3倍。氯贝丁酯治疗使SHR大鼠的SBP降低了26%±2%,蛋白尿降低了43%±9%,但对WKY大鼠无此作用。SHR大鼠的尿亚硝酸盐/硝酸盐排泄量比WKY大鼠高近2倍,氯贝丁酯治疗后分别进一步增加了30%±4%和48%±3%。此外,SHR大鼠中PPARα蛋白表达和PPARα活性显著低于WKY大鼠。氯贝丁酯治疗显著增加了SHR大鼠的PPARα蛋白表达和PPARα活性,但对WKY大鼠无此作用。此外,SHR大鼠主动脉环的血管收缩反应明显增强,氯贝丁酯治疗后减弱。
PPARα有助于调节SHR的血压和血管反应性,氯贝丁酯介导的血压和蛋白尿降低可能是通过增加一氧化氮生成实现的。